XML 35 R20.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Stock Plans | 12 Months Ended
--- | ---
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract] |
Stock Plans | Stock Plans The 2023 Management Equity Incentive Plan and its predecessor, the 2016 Management Equity Incentive Plan, provide for various forms of stock-based compensation for eligible employees through May 2033 including stock options, restricted stock awards, restricted stock units and performance stock units. The 2017 Non-Employee Directors’ Equity Incentive Plan provides for grants of stock options and restricted stock to non-employee directors through May 2027. Stock options are granted at market prices and expire after ten years. Stock options are exercisable beginning three years after the grant date. Restricted stock and restricted stock units are granted without payment to the Company and generally vest three years after the grant date. Restricted stock and restricted stock units are valued at the market value of the stock on the grant date. Performance stock units with a market condition are valued at an estimated fair value using a Monte Carlo simulation model. The final number of shares to be issued for performance stock units may range from zero to 240% of the target award based on achieving the specified performance targets over the performance period and further range based upon the achieved market metric over the performance period. In general, unvested stock options, restricted stock and performance stock units are forfeited if the participant’s employment with the Company terminates for any reason other than retirement, death or disability. We issue Treasury shares for stock option exercises and grants of restricted stock and performance stock. Please refer to Note 7—Capital Stock for further information regarding stock compensation share issuance. As of December 31, 2023, there were 1,869,407 and 68,439 shares, respectively, reserved for future grants under the management and non-employee directors’ equity incentive plans. Stock-based compensation expense was as follows:
(In thousands) | 2023 |  | 2022 |  | 2021
Restricted stock units | $ | 8,062 |  |  | $ | 6,488 |  |  | $ | 5,797 |
Stock options | — |  |  | 49 |  |  | 81 |
Performance stock units | 21,961 |  |  | 13,113 |  |  | 13,030 |
Total stock-compensation expense before income taxes | 30,023 |  |  | 19,650 |  |  | 18,908 |
Income tax benefit | 7,356 |  |  | 4,814 |  |  | 4,633 |
Total stock-compensation expense, net of income tax benefit | $ | 22,667 |  |  | $ | 14,836 |  |  | $ | 14,275 |
We did not capitalize any stock-based compensation expense, and all expense is included in Selling, general and administrative expense in the Consolidated Statements of Income. A summary of option activity follows:
| Shares |  | Weighted Average Exercise Price |  | Exercisable at Year-end
Outstanding January 1, 2021 | 283,998 |  |  | $ | 46.23 |  |  |
Exercised | (122,087) |  |  | 47.25 |  |  |
Forfeited | (210) |  |  | 43.75 |  |  |
Outstanding December 31, 2021 | 161,701 |  |  | 45.47 |  |  | 161,347 |
Exercised | (103,545) |  |  | 44.91 |  |  |
Outstanding December 31, 2022 | 58,156 |  |  | 46.48 |  |  | 58,156 |
Exercised | (31,394) |  |  | 46.90 |  |  |
Forfeited | (226) |  |  | 49.44 |  |  |
Outstanding December 31, 2023 | 26,536 |  |  | $ | 45.95 |  |  | 26,536 |
For various exercise price ranges, characteristics of outstanding and exercisable stock options at December 31, 2023 were as follows:
| Stock Options Outstanding and Exercisable
Range of Exercise Prices | Shares |  | Weighted-Average
Exercise Price |  | Remaining Life
$33.01 – $45.00 | 17,820 |  |  | $ | 44.50 |  |  | 1.66
$45.01 – $57.93 | 8,716 |  |  | 48.92 |  |  | 1.73
$33.01 – $57.93 | 26,536 |  |  | $ | 45.95 |  |  | 1.68
Cash received from the exercise of stock options was $1.5 million, $4.7 million and $5.8 million for the years ended December 31, 2023, 2022 and 2021, respectively. The tax benefit we realized from these exercises was $0.9 million, $1.9 million and $4.3 million for the years ended December 31, 2023, 2022 and 2021, respectively. Stock options become exercisable when they are vested. The aggregate intrinsic value of stock options exercisable and outstanding at December 31, 2023 was $3.3 million. Restricted stock awards and restricted stock units are valued at the market value of the stock on the grant date. A summary of restricted stock unit activity follows:
| Shares |  | Weighted Average Grant Date Fair Value
Unvested January 1, 2021 | 146,191 |  |  | $ | 105.83 |
Granted | 43,146 |  |  | 167.13 |
Vested | (65,225) |  |  | 95.43 |
Forfeited | (5,769) |  |  | 132.54 |
Unvested at December 31, 2021 | 118,343 |  |  | 132.62 |
Granted | 87,697 |  |  | 130.28 |
Vested | (51,369) |  |  | 113.96 |
Forfeited | (8,785) |  |  | 139.66 |
Unvested at December 31, 2022 | 145,886 |  |  | 137.36 |
Granted | 81,150 |  |  | 142.92 |
Vested | (43,107) |  |  | 126.27 |
Forfeited | (10,078) |  |  | 140.28 |
Unvested at December 31, 2023 | 173,851 |  |  | $ | 142.73 |
A summary of performance stock unit activity follows:
| Shares |  | Weighted Average Grant Date Fair Value
Unvested at January 1, 2021 | 200,212 |  |  | $ | 104.69 |
Granted | 52,309 |  |  | 175.59 |
Vested | (64,543) |  |  | 85.41 |
Performance adjustments | 5,357 |  |  | 88.45 |
Unvested at December 31, 2021 | 193,335 |  |  | 129.86 |
Granted | 81,504 |  |  | 142.38 |
Vested | (55,447) |  |  | 101.38 |
Performance adjustments | (22,147) |  |  | 99.84 |
Forfeited | (18,485) |  |  | 147.66 |
Unvested at December 31, 2022 | 178,760 |  |  | 146.28 |
Granted | 77,654 |  |  | 132.39 |
Vested | (53,407) |  |  | 127.36 |
Performance adjustments | (3,009) |  |  | 127.40 |
Forfeited | (10,777) |  |  | 147.06 |
Unvested at December 31, 2023 | 189,221 |  |  | $ | 146.17 |
The 2023 performance adjustments above relate primarily to 2020 performance unit awards which vested in the first quarter of 2023 at 94.9% of the target award based on both cumulative performance against EBITDA margin and revenue growth targets and MSA's TSR during the three-year performance period. During the years ended December 31, 2023, 2022 and 2021, the total intrinsic value of stock options exercised (the difference between the market price on the date of exercise and the option price paid to exercise the option) was $3.7 million, $8.6 million and $13.0 million, respectively. The fair values of restricted stock vested during the years ended December 31, 2023, 2022 and 2021 were $5.4 million, $5.9 million and $6.2 million, respectively. The fair value of performance stock units vested during the years ended December 31, 2023, 2022 and 2021 was $6.8 million, $5.6 million and $5.5 million, respectively. On December 31, 2023, there was $21.1 million of unrecognized stock-based compensation expense. The weighted average period over which this expense is expected to be recognized was approximately 1.7 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration